Add SMA to the heel prick test in the UK


Add SMA to the heel prick test in the UK
The Issue
In the past six months, I've come across heartbreaking stories from two UK mothers, known as Nanny Aimes and Jesy Nelson, whose babies were diagnosed with Spinal Muscular Atrophy (SMA) Type 1 much later than they should have been. The devastating impact of these late diagnoses cannot be overstated; early detection through newborn screening could significantly change the trajectory of these children's lives.
SMA is a severe genetic condition characterized by progressive muscle wasting and weakness due to the loss of motor neurons. It is the leading genetic cause of death in infants worldwide. According to SMA UK, about 1 in every 6,000-10,000 babies are born with SMA. The importance of early detection is paramount; treatments are most effective when administered soon after birth, often before the onset of symptoms.
Currently, the heel prick test, also known as the newborn blood spot test, screens for several other conditions in the UK. However, SMA is conspicuously absent from this list. In countries like the United States, where SMA has been added to newborn screening panels, early intervention has led to significantly improved outcomes. By adding SMA to the heel prick test in the UK, we can offer the same hope.
We call on the NHS and relevant policymakers to amend the newborn screening program to include SMA. This change can facilitate early intervention, providing families with the tools they need from the moment their child is born. It is not just about saving lives; it's about ensuring these children have the best possible quality of life.
By detecting SMA early, we can reduce the emotional and financial burdens on families and the healthcare system. The benefits of early detection and treatment are clear, and the emotional distress that accompanies a late diagnosis can be avoided.
Together, we can push for a change that will help future generations of children born in the UK. Let's make sure no more families have to endure what Nanny Aimes and Jesy Nelson have. Please join us in calling for SMA to be included in the UK heel prick test. Sign this petition today and be a part of this crucial change towards early detection and intervention for SMA.
SMA is a severe genetic condition characterized by progressive muscle wasting and weakness due to the loss of motor neurons. It is the leading genetic cause of death in infants worldwide. According to SMA UK, about 1 in every 6,000-10,000 babies are born with SMA. The importance of early detection is paramount; treatments are most effective when administered soon after birth, often before the onset of symptoms.
Currently, the heel prick test, also known as the newborn blood spot test, screens for several other conditions in the UK. However, SMA is conspicuously absent from this list. In countries like the United States, where SMA has been added to newborn screening panels, early intervention has led to significantly improved outcomes. By adding SMA to the heel prick test in the UK, we can offer the same hope.
We call on the NHS and relevant policymakers to amend the newborn screening program to include SMA. This change can facilitate early intervention, providing families with the tools they need from the moment their child is born. It is not just about saving lives; it's about ensuring these children have the best possible quality of life.
By detecting SMA early, we can reduce the emotional and financial burdens on families and the healthcare system. The benefits of early detection and treatment are clear, and the emotional distress that accompanies a late diagnosis can be avoided.
Together, we can push for a change that will help future generations of children born in the UK. Let's make sure no more families have to endure what Nanny Aimes and Jesy Nelson have. Please join us in calling for SMA to be included in the UK heel prick test. Sign this petition today and be a part of this crucial change towards early detection and intervention for SMA.
Savannah ThomsonPetition Starter
3,159
The Issue
In the past six months, I've come across heartbreaking stories from two UK mothers, known as Nanny Aimes and Jesy Nelson, whose babies were diagnosed with Spinal Muscular Atrophy (SMA) Type 1 much later than they should have been. The devastating impact of these late diagnoses cannot be overstated; early detection through newborn screening could significantly change the trajectory of these children's lives.
SMA is a severe genetic condition characterized by progressive muscle wasting and weakness due to the loss of motor neurons. It is the leading genetic cause of death in infants worldwide. According to SMA UK, about 1 in every 6,000-10,000 babies are born with SMA. The importance of early detection is paramount; treatments are most effective when administered soon after birth, often before the onset of symptoms.
Currently, the heel prick test, also known as the newborn blood spot test, screens for several other conditions in the UK. However, SMA is conspicuously absent from this list. In countries like the United States, where SMA has been added to newborn screening panels, early intervention has led to significantly improved outcomes. By adding SMA to the heel prick test in the UK, we can offer the same hope.
We call on the NHS and relevant policymakers to amend the newborn screening program to include SMA. This change can facilitate early intervention, providing families with the tools they need from the moment their child is born. It is not just about saving lives; it's about ensuring these children have the best possible quality of life.
By detecting SMA early, we can reduce the emotional and financial burdens on families and the healthcare system. The benefits of early detection and treatment are clear, and the emotional distress that accompanies a late diagnosis can be avoided.
Together, we can push for a change that will help future generations of children born in the UK. Let's make sure no more families have to endure what Nanny Aimes and Jesy Nelson have. Please join us in calling for SMA to be included in the UK heel prick test. Sign this petition today and be a part of this crucial change towards early detection and intervention for SMA.
SMA is a severe genetic condition characterized by progressive muscle wasting and weakness due to the loss of motor neurons. It is the leading genetic cause of death in infants worldwide. According to SMA UK, about 1 in every 6,000-10,000 babies are born with SMA. The importance of early detection is paramount; treatments are most effective when administered soon after birth, often before the onset of symptoms.
Currently, the heel prick test, also known as the newborn blood spot test, screens for several other conditions in the UK. However, SMA is conspicuously absent from this list. In countries like the United States, where SMA has been added to newborn screening panels, early intervention has led to significantly improved outcomes. By adding SMA to the heel prick test in the UK, we can offer the same hope.
We call on the NHS and relevant policymakers to amend the newborn screening program to include SMA. This change can facilitate early intervention, providing families with the tools they need from the moment their child is born. It is not just about saving lives; it's about ensuring these children have the best possible quality of life.
By detecting SMA early, we can reduce the emotional and financial burdens on families and the healthcare system. The benefits of early detection and treatment are clear, and the emotional distress that accompanies a late diagnosis can be avoided.
Together, we can push for a change that will help future generations of children born in the UK. Let's make sure no more families have to endure what Nanny Aimes and Jesy Nelson have. Please join us in calling for SMA to be included in the UK heel prick test. Sign this petition today and be a part of this crucial change towards early detection and intervention for SMA.
Savannah ThomsonPetition Starter
Support now
3,159
Supporter Voices
Petition Updates
Share this petition
Petition created on 4 January 2026